USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
26 Apr 2023 | 02:45 PM GMT

Masterclass: Making Precision Medicine Accessible and Affordable

Anchored by:

Jason Foster
CEO
ORI BIOTECH

Participants:

Jason Foster CEOOri Biotech
Jason Foster
CEOOri Biotech
Julie Carty Head of GrowthHLTH Community
Julie Carty
Head of GrowthHLTH Community
Angelie Singh Co-founderAGEN-C Project
Angelie Singh
Co-founderAGEN-C Project
Avi Tewarie Associate Director - Consumer EngagementEli Lilly
Avi Tewarie
Associate Director - Consumer EngagementEli Lilly
Colm Galligan Chief Medical Officer & Co-FounderRemedyBio
Colm Galligan
Chief Medical Officer & Co-FounderRemedyBio
DD
David Deuchler Managing Director Gilmartin Group
DD
David Deuchler
Managing Director Gilmartin Group
Jorge Juan Fernández García Chief Innovation OfficerHospital Clínic Barcelona
Jorge Juan Fernández García
Chief Innovation OfficerHospital Clínic Barcelona
Martin Kelly FounderAforja
Martin Kelly
FounderAforja
RH
Ryan Halsted Managing DirectorGilmartin Group
RH
Ryan Halsted
Managing DirectorGilmartin Group

About this Meeting

One-size-fits-all approach is outdated; every patient is different. The healthcare industry needs innovative technologies, such as cell and gene therapy, to deliver more personalized treatments to patients. Precision medicine holds promise to solve many challenges in healthcare, and the expectations are that it will help the industry move beyond traditional population medicine to deliver better health outcomes. However, precision medicine comes with huge accessibility and affordability challenges. How can we enable patient access to this new generation of personalized treatments? How can we seamlessly scale from development to commercialisation?   

Join this masterclass led by Jason Foster (CEO at Executive Director at Ori Biotech), who will walk us through:  
  • Precision medicine as first line therapies: what does it take to make precision medicines first line therapies? 
  • Clinical efficacy vs. ability to supply: which is more important in cell and gene therapy? 
  • How could distributed/local/PoC manufacturing have a positive impact? 
  • What is the role of digital in enabling access?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.